Podcasts

Recent Episodes

Chandler Park, MD; Pashtoon Kasi, MD, MS

September 25, 2026

Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management

Nataliya Uboha, MD, PhD, discusses zanidatamab-based regimens, their recent approval, and the HERIZON-GEA-01 trial in gastric cancer.

September 24, 2026

Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer

Narjust Florez, MD, and Jonathan Wesley Riess, MD, MS

September 24, 2026

Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC

September 23, 2026

INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management

September 22, 2026

Integrating Precision Pathways in HER2+ Gastroesophageal Adenocarcinoma—Testing, Treatment, and Supportive Care

September 21, 2026

Pancreatic Cancer Experts Map Treatment Sequencing With Liposomal Irinotecan and Beyond

September 17, 2026

Fast-Moving Treatment Advances Shape B-Cell Lymphoma Care

Sara Nunnery, MD, MSCI; Matthew Kurian, MD

September 15, 2026

Oncology's AI Adoption Hinges on Weighing Benefits vs Risks and Confronting Limitations

Samantha A. Armstrong, MD; Karine Tawagi, MD

September 14, 2026

Metastatic Non-Small Cell Lung Cancer 2026 UPDATE

September 11, 2026

The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

All series

All Podcasts

Harry P. Erba, MD, PhD, professor, medicine, Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, director, Leukemia Program, director, Phase I Development in Hematologic Malignancies; member, Duke Cancer Institute

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

ByHarry Erba, MD, PhD

November 20th 2025

Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

ByJustin Taylor, MD

November 19th 2025

Justin Taylor, MD discusses how patients use AI to seek cancer information, its accuracy and limitations, and the implications for hematologic malignancy care.

Martha K. Terris, MD, FACS, department chair, professor, Department of Urology, Witherington Distinguished Chair in Urology, co-director, Cancer Center, Medical College of Georgia at Augusta University

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 18th 2025

Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.

Benjamin P. Levy, MD Kamel Abou Hussein, MD Victoria Rizk, MD

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

ByBenjamin P. Levy, MD,Victoria Rizk, MD,Kamel Abou Hussein, MD

November 17th 2025

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

ByBenjamin P. Levy, MD,Jonathan Lee, MD, MSc

November 14th 2025

Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.

Benjamin P. Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital, associate professor, oncology, Johns Hopkins University School of Medicine; Scott T. Tagawa, MD, MS, FACP, FASCO, professor, medicine and urology, Weill Cornell Medicine, attending physician, NewYork-Presbyterian – Weill Cornell Medical Center

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

ByBenjamin P. Levy, MD,Scott T. Tagawa, MD

November 13th 2025

Drs Levy and Tagawa discuss the rapidly evolving treatment paradigms for prostate cancer and RCC live at the 43rd Annual Chemotherapy Foundation Symposium.

Ursula A. Matulonis, MD, chief, Division of Gynecologic Oncology, Brock-Wilcon Family Chair, Dana-Farber Cancer Institute, professor, medicine, Harvard Medical School; Taymaa May, MD, MSc, director, Ovarian Cancer Surgery, Division of Surgical Oncology, Brigham and Women’s Hospital, associate professor, Harvard Medical School

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

ByUrsula A. Matulonis, MD,Taymaa May, MD, MSc

November 13th 2025

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

D. Ross Camidge, MD, PhD; Mark Socinski, MD, medical oncologist, executive medical director, AdventHealth Cancer Institute

How a Career Dedicated to Patient Connections and Research Advances Has Improved Lung Cancer Care: With D. Ross Camidge, MD, PhD; and Mark Socinski, MD

ByRoss Camidge, MD, PhD,Mark A. Socinski, MD

November 12th 2025

Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory and the personal influences that helped him arrive where he is today.

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 11th 2025

Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis.

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, University of Illinois

Urothelial ESMO 2025 Updates

BySamantha A. Armstrong, MD,Karine Tawagi, MD

November 10th 2025

OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.

Kevin Kalinsky, MD, MS, FASCO, professor, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; director, Glenn Family Breast Center, Louisa and Rand Glenn Family Chair in Breast Cancer Research, Winship Cancer Institute

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

ByKevin Kalinsky, MD, MS

November 7th 2025

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

Stephen Liu, MD, associate professor, medicine, Georgetown University; director, Thoracic Oncology, head, Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

ByStephen Liu, MD

November 6th 2025

Dr Liu discusses the potential role for zidesamtinib for the treatment of patients with advanced non–small cell lung cancer harboring ROS1 rearrangements.

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

ByHira Mian, MD

November 6th 2025

Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.

Sikander Ailawadhi, MD, consultant, Division of Hematology/Oncology, Department of Internal Medicine, consultant, Department of Cancer Biology, professor, medicine, Mayo Clinic; Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO nurse practitioner, Multiple Myeloma Program, Cleveland Clinic

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

BySikander Ailawadhi, MD,Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

November 5th 2025

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Medical College of Georgia at Augusta University

Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS

ByMartha K. Terris, MD, FACS

November 4th 2025

Martha K. Terris, MD, FACS, discusses unique considerations for bladder cancer diagnosis and treatment among women

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Oncology Experts Dive Into Top Data From ESMO 2025

ByPaolo Tarantino, MD,Dana Chase, MD,Andrew W. Hahn, MD,Andrea Necchi, MD,Nicoletta Colombo, MD, PhD

November 3rd 2025

At the 2025 ESMO Congress, leading oncologists reflected on data expected to redefine practice across breast, genitourinary, and gynecologic malignancies.

Neal Shore, MD, FACS, medical director, Carolina Urologic Research Center

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

ByNeal Shore, MD, FACS

October 31st 2025

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Ziad Hanhan, MD, thoracic surgeon, Hackensack Meridian Health, chairman, Surgery at Bayshore Medical Center, chief, Thoracic Surgery, Riverview Medical Center; Thomas Bauer, MD, chair, surgery, Jersey Shore University Medical Center and Hackensack Meridian Health School of Medicine; Rachel NeMoyer, MD, thoracic surgeon, Hackensack Meridian Health

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

ByZiad Hanhan, MD,Thomas Bauer, MD,Rachel NeMoyer, MD

October 30th 2025

Drs Hanhan, Bauer, and NeMoyer discuss the ins and outs of lung cancer diagnosis, surgical management, and evolving treatment paradigms.

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

ByAmit Mehta, MD

October 29th 2025

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

Armeen Mahvash, MD, professor, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center; assistant professor, Department of Diagnostic and Interventional Imaging, The University of Texas Medical School at Houston

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

ByArmeen Mahvash, MD

October 27th 2025

Dr Mahvash discusses the FDA approval of SIR-Spheres Y-90 resin microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Vishal A. Patel, MD, FAAD, FACMS, associate professor, dermatology, GW School of Medicine & Health Sciences; director, Cutaneous Oncology Program, GW Cancer Center

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS

ByVishal A. Patel, MD, FAAD, FACMS

October 23rd 2025

Dr Patel discusses the clinical relevance of the FDA approval of adjuvant cemiplimab for the management of high-risk cutaneous squamous cell carcinoma.

Eunice Wang, MD, professor, oncology, leader, Leukemia Clinical Disease Team, chief, leukemia, Department of Medicine, assistant member, Tumor Immunology Program, Department of Immunology, Roswell Park Comprehensive Cancer Center; associate professor, Department of Medicine, academic scholar, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

ByEunice Wang, MD

October 22nd 2025

Dr Wang discusses the prevalence of secondary AML, unmet needs for patients with this disease, and how CPX-351 has generated improved outcomes vs 7+3.

Metastatic Breast Cancer 2025 UPDATE

BySamantha A. Armstrong, MD,Karine Tawagi, MD

October 20th 2025

In this episode, Two Onc Docs review the current management of metastatic breast cancer, emphasizing treatment strategies across molecular subtypes.

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

ByJ.Thaddeus Beck, MD, FACP

October 16th 2025

J. Thaddeus Beck, MD, FACP, about the FDA approval of subcutaneous pembrolizumab.

Girindra Raval, MD; Anand Jillella, MD, J. Harold Harrison, MD Distinguished University Chair in Medicine, professor, medicine & pediatrics, chief, Division of Hematology/Oncology, Augusta University Medical College of Georgia

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

ByGirindra Raval, MD,Anand Jillella, MD

October 15th 2025

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Dana M. Chase, MD; Premal H. Thaker, MD, MS; Zev Wainberg, MD; Sagus Sampath, MD

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

ByDana Chase, MD,Premal H. Thaker, MD, MS,Zev A. Wainberg, MD,Sagus Sampath, MD

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Joseph Jacob, MD, MCR, associate professor, urology, director, Urologic Oncology, Department of Urology, State University of New York Upstate Medical University

FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

ByJoseph Jacob, MD, MCR

October 9th 2025

Dr Jacob discusses the significance of the FDA approval of the gemcitabine intravesical system for BCG-unresponsive non–muscle-invasive bladder cancer.

Lyudmila Bazhenova, MD, clinical professor, medicine, the University of California San Diego (UCSD); medical oncologist, UCSD Moores Cancer Center

FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD

ByLyudmila A. Bazhenova, MD

October 8th 2025

Dr Bazhenova discusses the FDA approval of sunvozertinib for patients with EGFR-mutated metastatic non–small cell lung cancer.

Kanwal P. S. Raghav, MBBS, MD, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine; associate vice president, Department of Ambulatory Medical Operations; executive medical director, Department of Ambulatory Treatment Centers, The University of Texas MD Anderson Cancer Center

Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

ByKanwal Raghav, MBBS, MD

October 6th 2025

Dr Raghav discusses the role of fruquintinib in the treatment of adult patients with pretreated, metastatic colorectal cancer.

Anne Chiang, MD, PhD, associate professor, medicine, Section of Medical Oncology, associate cancer center director, Clinical Initiatives, Yale School of Medicine; Stephen Liu, MD, associate professor, medicine, Georgetown University, director, Thoracic Oncology, head, Developmental Therapeutics, the Georgetown Lombardi Comprehensive Cancer Center

FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD

ByAnne Chiang, MD,Stephen Liu, MD

October 2nd 2025

Drs Chiang and Liu discuss the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.

Podcasts

Recent Episodes

All series

Oncology Unplugged With Dr Chandler Park

Pediatrics

Breast Cancer Briefing

Marvels in Medicine

One for Minutes With Markman

Talking Tumors

Ask Me Anything

Biomarker Consortium

State of the Science Summits

From Discovery to Delivery: Charting Progress in Gynecologic Oncology

OncLive on Air Powered by PER

Roundtable Discussions

Fellowship

Disparities

Rare Cancers

Women In Oncology

Conference Perspectives

OncClub

Oncology Expert Insights

FDA Approval Insights

Blood Club

Two Onc Docs

Cancer, Character, and Calling

How This Is Building Me

All Podcasts

FDA Approval Insights: Ziftomenib in NPM1+ R/R AML: With Harry P. Erba, MD, PhD

Insights and Implications of AI’s Expanding Role in Hematologic Malignancy Care: With Justin Taylor, MD

Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS

Advances in Breast Cancer ADCs and Endocrine Therapy Take Center Stage at CFS: With Benjamin P. Levy, MD; Kamel Abou Hussein, MD; and Victoria Rizk, MD

Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc

PSMA Theranostics, ctDNA Testing, and Combination Regimens in GU Oncology Spark Conversation at CFS: With Benjamin P. Levy, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

How a Career Dedicated to Patient Connections and Research Advances Has Improved Lung Cancer Care: With D. Ross Camidge, MD, PhD; and Mark Socinski, MD

Unique Challenges Characterize Treatment Outcomes for Women With Bladder Cancer: With Martha K. Terris, MD, FACS

Urothelial ESMO 2025 Updates

Research Innovations Spark Promise for Broadening the HR+ Breast Cancer Armamentarium Post-CDK4/6 Inhibition: With Kevin Kalinsky, MD, MS, FASCO

ARROS-1 Data Show Zidesamtinib's Favorable Safety Profile, Spark Discussion to Clarify Its Role in ROS1+ NSCLC: With Stephen Liu, MD

Dynamic Frailty Assessment Underscores Need for Ongoing Evaluation in Transplant-Ineligible Multiple Myeloma: With Hira Mian, MD, MSc, FRCPC

Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

Bladder Cancer Symptom Awareness and Testing Are Crucial for Early Detection in Women: With Martha K. Terris, MD, FACS

Oncology Experts Dive Into Top Data From ESMO 2025

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

Early Detection, Surgical Innovation, and Multidisciplinary Collaboration Evolve Lung Cancer Care: With Ziad Hanhan, MD, Thomas Bauer, MD, and Rachel NeMoyer, MD

Evolving Research Paradigms, Real-World Data, and Multidisciplinary Collaboration Enhance Bladder Cancer Management: With Amit Mehta, MD

FDA Approval Insights: Y-90 Resin Microspheres for Unresectable HCC: With Armeen Mahvash, MD

FDA Approval Insights: Adjuvant Cemiplimab for High-Risk CSCC: With Vishal A. Patel, MD, FAAD, FACMS

Evolving Treatment Strategies and Novel Therapies Reshape Secondary AML Management: With Eunice Wang, MD

Metastatic Breast Cancer 2025 UPDATE

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

FDA Approval Insights: Sunvozertinib in EGFR-Mutated Metastatic NSCLC: With Lyudmila Bazhenova, MD

Sequencing, Efficacy, and Safety Data May Further Evolve the Role of Fruquintinib in CRC: With Kanwal P. S. Raghav, MBBS, MD

FDA Approval Insights: Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC: With Anne Chiang, MD, PhD; and Stephen Liu, MD

Trending on OncLive

Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC

Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma

Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma

FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma